Pirfenidone for diabetic nephropathy. - Wikidata - wikimedia - TriplyDB

Pirfenidone for diabetic nephropathy.

Pirfenidone for diabetic nephropathy.

http://www.wikidata.org/entity/Q35012444

about

Role and New Insights of Pirfenidone in Fibrotic Diseases Vascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxide Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis TGF-β/Smad signaling in renal fibrosis Inhibitors/antagonists of TGF-β system in kidney fibrosis Present and future in the treatment of diabetic kidney disease N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes Improvements in the Management of Diabetic Nephropathy Role of bone morphogenetic protein-7 in renal fibrosis Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats Mefunidone attenuates tubulointerstitial fibrosis in a rat model of unilateral ureteral obstruction Therapeutic Modalities in Diabetic Nephropathy: Future Approaches.Fibrosis-related biomarkers and risk of total and cause-specific mortality: the cardiovascular health study Fibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study.Fluorofenidone offers improved renoprotection at early interventions during the course of diabetic nephropathy in db/db mice via multiple pathways Emerging drugs for chronic kidney disease.Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.Urinary microRNA profiling in the nephropathy of type 1 diabetes.Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1.Renal function can improve at any stage of chronic kidney disease.Therapeutic targets for treating fibrotic kidney diseases Epigenetics in diabetic kidney disease.Signaling mechanisms in the regulation of renal matrix metabolism in diabetes.Fibrosis-related biomarkers and large and small vessel disease: the Cardiovascular Health Study.Antioxidants in kidney diseases: the impact of bardoxolone methyl.Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes Diabetic nephropathy: What does the future hold?Comprehensive approach to diabetic nephropathy.Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis.Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis.TGF-β signaling in the kidney: profibrotic and protective effects Discoidin domain receptor-1 and periostin: new players in chronic kidney disease Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease miR-34c attenuates epithelial-mesenchymal transition and kidney fibrosis with ureteral obstruction.What are new avenues for renal protection, in addition to RAAS inhibition?Cellular and molecular mechanisms of diabetic glomerulopathy.Pathophysiology of the aging kidney and therapeutic interventions.Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications.

P2860

Q26774154-61FD65CD-A87B-4DA8-9061-315EF6DDBFB3 Q26783581-FC1C8865-261B-44F0-AFE0-8B565F1652EA Q26849378-D84A349B-716C-415C-827B-E070146FFD2F Q26851198-AD1C71DF-4D13-4056-A9BE-233CDEEEB588 Q26852400-286E8709-F61D-4AD4-BC38-03F97BFBD69E Q26864133-DD8C8A8E-7790-444C-8E98-E800A15D0EFA Q27008887-1E786E67-E359-4D59-8689-CE42BC40390A Q28080717-A519D23A-B664-47C5-9BA9-2A159BD73736 Q28080865-C0210256-E5D8-4067-B263-E464901C5C7C Q28086840-097C78F8-9153-4F63-8434-8FBE5EB07583 Q28536610-E384F43E-F43D-4273-89FA-B87B8C3F5FB0 Q28547858-B20923C4-95E1-4871-9212-806DCEADB81F Q30423005-B71F2B5C-58AA-400C-8AE8-C0FF088F4E4A Q33676034-A54C22FC-786D-4B0B-AC3F-5FF149A475DB Q34076151-997B0746-7B81-4A48-98B0-C9D6EA036FAF Q34408514-F6F0D3CA-7522-4510-B75F-DD2FEBCF9A30 Q34420383-ED270C70-E29E-4543-9F18-47363E05CC95 Q34537906-99B19340-10DD-4E7B-A4CD-7F3B08F417C2 Q34566051-D9C0CC45-9D48-4C1A-9D23-2ED19E77C194 Q34634066-19156663-58A4-4958-9175-60EBE4A34040 Q35069799-AAA5C5D0-C1DC-4186-8F5A-5E057135EACD Q35079607-83BEDE66-3440-4341-9497-B59529948CD3 Q35647853-9C4720A1-ADC3-442C-80CC-32C41617CF2E Q35791976-064B7858-77B1-4459-99F4-66426BCC14B8 Q35897206-ACCE6599-9BDC-4D49-9297-6E6058FF72DC Q36026304-7F7CE170-E2D1-4E3F-8362-CA9EA89710CB Q36297539-D2545BC4-94E2-4B3A-92B6-6AADB6397257 Q36339470-111EB60A-7961-46FA-AEBF-8D302C5871FE Q36441616-396DE116-93A7-4595-82CF-B9EF2CDD97A1 Q36466019-3C4F0287-8FB2-43F2-AF1F-DDDCDC0123E6 Q36589609-A1207EC7-E8BC-4046-9338-3F31F1F6DCA2 Q36763871-8D786E95-BF12-4866-9F0B-3DA43B1CAB79 Q36775661-53724500-3D4E-4D2D-B5C2-77BBEB60DD98 Q36801573-98313EAA-0CBA-4925-9390-D56DFC797EAB Q37260216-BA4292D0-F165-4FB6-946E-0F4530AD8CC0 Q37681848-D1CE4BB2-5EC7-441F-AA52-3721C384E2C1 Q37980677-E04C58B2-A112-409B-98BB-BE2EBD519743 Q38010045-774F8A11-8084-4BE1-87C2-9F8B577D7669 Q38053074-5F19A067-788C-4F51-B3EA-4B49C27877A4 Q38054089-D95D1DFA-1D4D-4582-82F2-6DE1B6209505

P2860

Pirfenidone for diabetic nephropathy.

http://www.wikidata.org/entity/Q35012444

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pirfenidone for diabetic nephropathy.

@ast

Pirfenidone for diabetic nephropathy.

@en

type

label

Pirfenidone for diabetic nephropathy.

@ast

Pirfenidone for diabetic nephropathy.

@en

prefLabel

Pirfenidone for diabetic nephropathy.

@ast

Pirfenidone for diabetic nephropathy.

@en

P1433

Q35012444-5282BA89-46AB-448E-B42F-BA4D074B96E4

P1476

Q35012444-A26844BF-2C2F-4A94-900F-74A596084D58

P2093

Q35012444-04C541BE-62F7-4715-A2FC-BF103A349A3E

Q35012444-08DE1838-7B14-4673-9D92-B6F0D4F13D22

Q35012444-1A054A10-AB6B-4CBF-83CE-B6DD6D61CC23

Q35012444-5638D6B0-48B0-483E-9243-3D6F15B6DC7C

Q35012444-61FF109A-8EFA-4259-83A0-CBF9D19E606D

Q35012444-7021F837-C271-400E-8E9A-CC15B32356D7

Q35012444-7B0C9BE1-7555-4F00-823A-74A10847330F

Q35012444-84AEAECA-572D-4289-8937-2A986FC07F0A

Q35012444-B5CE61E2-FE3B-4808-B594-BDDCB6239BD9

Q35012444-D013196D-B600-46F8-847A-F1E70C429A2F

P2860

Q35012444-03CA9C16-6598-4008-AEA2-C1518403A355

Q35012444-06459DBB-6A6A-42C2-8A4A-06DFEA7EF17E

Q35012444-0B6D4DF0-F0AF-4D4A-B619-62C0362CE7AA

Q35012444-18726A58-77CE-4B62-80C6-C0E456848E63

Q35012444-28672DFD-311D-4884-A9FA-04F324B437EB

Q35012444-293A4433-C5DE-471C-84E7-7B518ECC60E8

Q35012444-2A016CE7-B3C8-4912-91B4-5257C5B15663

Q35012444-3F21DE79-F217-43E1-B5DF-6106BAC42EF1

Q35012444-455C58F9-15BC-4CFF-BA30-C4F207027F90

Q35012444-4D182FEE-5CAB-4691-AE8F-4CC2EF2A9399

P304

Q35012444-F069366F-0398-461B-8775-BBA59474D5CC

P31

Q35012444-8D914B95-5F91-42B1-B3A9-E994708505CC

P356

Q35012444-D81AEA4D-EC6F-4C69-9E3F-2304C6157C60

P433

Q35012444-5F18FE56-4F83-4686-BD3A-43BD387BAD0C

P478

Q35012444-92FA4724-6594-4D4A-A010-6EEDA24D4CD7

P50

Q35012444-44817414-8355-4FFE-A1CC-0501C1E95CA2

Q35012444-7F6BB37A-9AC5-4C8C-9607-3A356A336944

Q35012444-D838A98A-8AF1-4F20-85EF-791B2BFBF9B6

Q35012444-E7AC7478-4902-4EC0-A41E-9D37B63A0950

P577

Q35012444-6DF80FBB-42B1-4DBA-BEB1-7BEC87135206

P698

Q35012444-03890FB6-D83F-4B39-8D9D-57670D2F707F

P932

Q35012444-4717179C-DCB9-4A70-B3BE-CADAF58C0F53

P356

P1433

Journal of the American Society of Nephrology

P1476

Pirfenidone for diabetic nephropathy.

@en

P2093

Barbara Francos

http://www.w3.org/2001/XMLSchema#string

Bonita Falkner

http://www.w3.org/2001/XMLSchema#string

Fernando C Fervenza

http://www.w3.org/2001/XMLSchema#string

Kumar Sharma

http://www.w3.org/2001/XMLSchema#string

Michael Donohue

http://www.w3.org/2001/XMLSchema#string

Monique Cho

http://www.w3.org/2001/XMLSchema#string

Ronghui Xu

http://www.w3.org/2001/XMLSchema#string

Satish Ramachandrarao

http://www.w3.org/2001/XMLSchema#string

Shoba Sharma

http://www.w3.org/2001/XMLSchema#string

Stephen R Dunn

http://www.w3.org/2001/XMLSchema#string

P2860

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Longitudinal data analysis for discrete and continuous outcomes

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Testing for random dropouts in repeated measurement data.

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro.

The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.

Role of angiotensin II in glomerular injury.

Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse.

P304

1144-1151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2010101049

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey B. Kopp

P577

2011-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21511828

http://www.w3.org/2001/XMLSchema#string

P932

3103734

http://www.w3.org/2001/XMLSchema#string